Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668395 · ClinicalTrials.gov registry record · NA
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
A NA study of HIV, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT00668395: Completed NA study of HIV, sponsored by Indiana University.
NCT00668395 is a NA study of HIV that has completed, run by Indiana University. The registered enrollment target is 73 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00668395, a NA study of HIV, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get rid of efavirenz from your body. This may render efavirenz and other medications ineffective. 2. To see how efavirenz interact with other drugs taken at the same time with it. 3. To see if genetic differences can change the way how the liver breaks down efavirenz and its interactions with other co-administered drugs.
Primary Outcome
Efavirenz clearance is a measure of rate of elimination of the drug from the body. We used this measure to evaluate differences in rate of elimination of efavirenz at a single dose and after multiple dosing within three CYP2B6 genotypes (CYP2B6\*1/\*1, \*1/\*6 and CYP2B6\*6/\*6). Efavirenz clearance was measured in normal metabolizer of CYP2B6 (CYP2B6\*1/\*1 genotype), intermediate metabolizer (CYP2B6\*1/\*6) and slow metabolizer (CYP2B6\*6/\*6) at a single 600 mg oral dose of efavirenz and then
Conditions Studied
Interventions
- DRUG Efavirenz
Study Locations (2)
Indiana
- Indiana Clinical Research Center (ICRC) - Indianapolis
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-04 |
| Phase | NA |
What the finished NCT00668395 record still lists
NCT00668395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (83% lower).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Efavirenz is the first listed.
NCT00668395 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00668395 about?
NCT00668395 is a clinical study titled "Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics". 1. To see how the liver breaks down efavirenz by an enzyme called CYP2B6. It is suggested that when Efavirenz is taken repeatedly it may increase the amount of CYP2B6 in your liver and thus speed up your liver's ability to get rid of efavirenz from your body. This may render efavirenz and other medi...
What is the current status of trial NCT00668395?
This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2007-05. Estimated completion is 2010-04.
What conditions does trial NCT00668395 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT00668395?
The interventions under investigation include: Efavirenz (DRUG).
Who is sponsoring clinical trial NCT00668395?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00668395 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00668395's enrollment target sits among peer trials
73 189th of 303 higher than 115 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia